Doximity Valuation
Is D2OC34 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of D2OC34 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: D2OC34 (R$46.4) is trading above our estimate of fair value (R$29.77)
Significantly Below Fair Value: D2OC34 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for D2OC34?
Key metric: As D2OC34 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is D2OC34's PE Ratio? | |
|---|---|
| PE Ratio | 51.7x |
| Earnings | US$174.11m |
| Market Cap | US$9.00b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 15.9x |
| Enterprise Value/EBITDA | 39.5x |
| PEG Ratio | 5.5x |
Price to Earnings Ratio vs Peers
How does D2OC34's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 44.4x | ||
RDOR3 Rede D'Or São Luiz | 18x | 17.8% | R$65.3b |
FLRY3 Fleury | 12x | 13.8% | R$7.4b |
SECT B Sectra | 122.7x | 21.2% | SEK 54.9b |
2413 M3 | 24.7x | 12.2% | JP¥967.6b |
D2OC34 Doximity | 51.7x | 9.4% | R$9.0b |
Price-To-Earnings vs Peers: D2OC34 is expensive based on its Price-To-Earnings Ratio (51.7x) compared to the peer average (44.4x).
Price to Earnings Ratio vs Industry
How does D2OC34's PE Ratio compare vs other companies in the Global Healthcare Services Industry?
| 3 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 3 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: D2OC34 is expensive based on its Price-To-Earnings Ratio (51.7x) compared to the Global Healthcare Services industry average (27.2x).
Price to Earnings Ratio vs Fair Ratio
What is D2OC34's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 51.7x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate D2OC34's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
CVS Health
US$73.0b
Provides health solutions in the United States.
CVSH34
US$32.94
7D
3.5%
1Y
-2.8%
Teladoc Health
US$1.8b
Provides virtual healthcare services worldwide.
T2DH34
US$2.06
7D
17.0%
1Y
-26.7%
Koninklijke Philips
€23.6b
Operates as a health technology company in North America, the Greater China, and internationally.
PHGN34
€152.70
7D
-0.8%
1Y
51.5%